CKLS121 / CK Life Sci, Sequencio Therapeutics - LARVOL DELTA

Claudin 6 vaccines effectively inhibit tumor growth in a syngeneic mouse colon cancer model (AACR 2026) - "Collectively, our findings demonstrate that CLDN6-targeted vaccines significantly suppressed the growth of CLDN6-positive tumors in mice. These results support CLDN6-targeted vaccines as a promising therapeutic strategy for CLDN6-positive cancers in humans, with their potential to be further validated in upcoming studies."

IO biomarker • Preclinical • Colon Cancer • Colorectal Cancer • Oncology • Solid Tumor • CLDN6 • IFNG

CK Life Sciences’ Investigational Cancer Vaccines Deliver Promising Results - New Preclinical Study Data to be Presented at the 2025 American Association for Cancer Research (AACR) Annual Meeting (ACCESSWIRE) - "In recent years, CK Life Sciences has regularly participated at the AACR Annual Meeting. The 2025 Annual Meeting will be held from 25-30 April. At the event, CK Life Sciences will exhibit posters highlighting data from preclinical studies of investigational cancer vaccines programs targeting (i) PRAME (Preferentially Expressed Antigen in Melanoma), (ii) PD-L1 (programmed cell death ligand 1), (iii) B7-H3 (B7 homolog 3) and (iv) Claudin 6 proteins, respectively....In addition, CK Life Sciences will be co-presenting with our research collaborator two posters showcasing our Artificial Intelligence (AI)-empowered platform for designing cancer vaccines."

Preclinical • Colon Cancer • Melanoma • Pancreatic Cancer